EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients
Posted in Drug Trial on September 9th, 2010EDAP TMS SA (Nasdaq:EDAP), the international director in corrective ultrasound, today reported favorable clinical outcomes benefit of patients treated with Ablatherm-HIFU. A out-and-out of 803 patients with localized prostate cancer, treated with Ablatherm-HIFU from 1993 until 2007, were reported in a library carried unlit near Dr. Sébastien Crouzet, Urologist at Edouard Herriot Asylum, Lyon, France. The interpretation has been published electronically Read the rest of this entry »
